KeyCorp Issues Positive Forecast for CryoPort (NASDAQ:CYRX) Stock Price

CryoPort (NASDAQ:CYRX) had its price objective lifted by KeyCorp from $17.00 to $20.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Other equities analysts have also recently issued reports about the company. BTIG Research boosted their target price on CryoPort from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, October 13th. Weiss Ratings upgraded CryoPort from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, October 8th. Piper Sandler raised CryoPort to a “buy” rating in a research note on Tuesday, October 13th. Roth Capital reaffirmed a “buy” rating and issued a $21.00 price target on shares of CryoPort in a research note on Friday, August 7th. Finally, Robert W. Baird set a $26.00 price target on shares of CryoPort in a report on Tuesday, October 13th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, CryoPort has a consensus rating of “Moderate Buy” and an average price target of $21.69.

CryoPort Trading Up 19.0%

Shares of CYRX stock traded up $3.05 during mid-day trading on Friday, reaching $19.10. The stock had a trading volume of 2,585,565 shares, compared to its average volume of 854,852. The firm has a market capitalization of $967.42 million, a PE ratio of -19.69 and a beta of 1.89. The stock’s 50-day moving average price is $16.98 and its two-hundred day moving average price is $13.46. CryoPort has a 52-week low of $7.61 and a 52-week high of $19.53.

CryoPort (NASDAQ:CYRX) last posted its earnings results on Thursday, November 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07). CryoPort had a negative return on equity of 7.20% and a negative net margin of 20.05%. The business had revenue of $50.22 million during the quarter, compared to the consensus estimate of $48.66 million. On average, equities research analysts forecast that CryoPort will post -0.83 earnings per share for the current year.

Insider Buying and Selling

In other CryoPort news, CEO Jerrell Shelton sold 28,800 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $14.91, for a total value of $429,408.00. Following the completion of the sale, the chief executive officer directly owned 1,201,814 shares in the company, valued at $17,919,046.74. This trade represents a 2.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. State of Alaska Department of Revenue bought a new position in shares of CryoPort in the 3rd quarter worth approximately $40,000. State of Wyoming bought a new stake in shares of CryoPort during the third quarter valued at approximately $81,000. Counterpoint Mutual Funds LLC bought a new stake in shares of CryoPort during the third quarter valued at approximately $324,000. Highland Investment Advisors LLC purchased a new stake in CryoPort in the second quarter worth $306,000. Finally, Diversified Trust Co grew its stake in CryoPort by 3.4% in the third quarter. Diversified Trust Co now owns 19,769 shares of the company’s stock worth $344,000 after purchasing an additional 657 shares during the period. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Key Headlines Impacting CryoPort

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Third-quarter revenue rose 14% year over year to $50.2 million, topping estimates of $48.66 million. Commercial cell and gene therapy revenue grew 20%; Cryoport supported a record 788 global clinical trials and 23 commercially approved therapies. Cryoport Reports Third Quarter 2026 Financial Results
• Positive Sentiment: The company raised its full-year 2026 revenue outlook to $197 million–$199 million, a key catalyst behind the favorable reaction to results. CryoPort Shares Rise After Q3 Revenue Beat, 2026 Guidance Raise
• Positive Sentiment: Analyst actions added support: Needham raised its price target to $28 from $19 and reiterated Buy, while KeyCorp lifted its target to $20 from $17 and maintained an Overweight rating. Needham Adjusts Price Target KeyCorp Rating
• Negative Sentiment: Adjusted earnings were a loss of $0.25 per share, missing consensus estimates of a $0.18–$0.19 loss and widening from a $0.18 loss a year earlier. The earnings shortfall may temper optimism around the revenue growth and raised outlook. CryoPort Reports Q3 Loss, Tops Revenue Estimates

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) provides temperature-controlled supply chain solutions for the life sciences industry. The company supports the transportation, storage and management of biological materials, including cell and gene therapies, vaccines, biologics, reproductive materials and other temperature-sensitive products.

Its offerings include cryogenic and refrigerated shipping containers, biological material storage, transportation logistics, shipment monitoring and related supply chain management services.